MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

BioMarin Pharmaceutical Inc

Отворен

СекторЗдравеопазване

62.79 0.22

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

61.49

Максимум

62.77

Ключови измерители

By Trading Economics

Приходи

19M

125M

Продажби

1.6M

747M

P/E

Средно за сектора

26.539

57.333

EPS

0.92

Марж на печалбата

16.719

Служители

3,040

EBITDA

39M

195M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+57.54% upside

Дивиденти

By Dow Jones

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-729M

11B

Предишно отваряне

62.57

Предишно затваряне

62.79

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

BioMarin Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.06.2024 г., 17:41 ч. UTC

Значими двигатели на пазара

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21.08.2024 г., 11:30 ч. UTC

Топ новини

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Сравнение с други в отрасъла

Ценова промяна

BioMarin Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

57.54% нагоре

12-месечна прогноза

Среден 97.58 USD  57.54%

Висок 126 USD

Нисък 70 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за BioMarin Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

16

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

61.5 / 63.39Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.